| Original language | English (US) |
|---|---|
| Pages (from-to) | 446-449 |
| Number of pages | 4 |
| Journal | American Journal of Kidney Diseases |
| Volume | 76 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2020 |
Bibliographical note
Funding Information:The authors appreciate the collaboration of Vilmundur Gudnason (University of Iceland, Reykjavik, Iceland & Icelandic Heart Association, Kopavogur, Iceland). The authors acknowledge the valuable contributions of the other investigators, staff, and participants of the MESA Study (supported by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from NHLBI, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from NCATS). A full list of participating investigators and institutions can be found at www.mesa-nhlbi.org .
Funding Information:
CKD- EPI was supported by grants U01DK067651 and U01DK35073 . AGES-Kidney was supported by a grant from NIH ( R01 DK082447 and supplement 01A1S1 to ASL), contract from the NIA ( N01-AG-1-2100 and HHSN27120120022C ), the Icelandic Heart Association (Hjartavernd) and the Icelandic Parliament (Althingi), and the American Recovery Act (3R01DK082447-01A1S1). MESA -Kidney was supported by R01DK087961 . HIV Study was funded by Gilead Sciences , Inc under an investigator-initiated protocol ( NCRR L1RR025752 ) and supported by the NCRR and the National Center for Advancing Translational Sciences , NIH , through grants UL1 RR025752 (Tufts Medical Center) and UL1 RR029887 (Mount Sinai School of Medicine) and also the Center for Clinical and Translational Sciences through grant UL1 RR025777 ( University of Alabama at Birmingham ). Support was also received from international collaborative research grant no. 13430720800 from the Science and Technology Commission of Shanghai Municipality to Shanghai Jiao Tong University School of Medicine, Multi-Center Clinical Research Project (No: DLY201510 ); grant ID 201502010 , National Health and Health Council (previously Ministry of Health), from 2015 through 2018; National Natural Science Foundation of China (grants 81771938 , 91846101 , 81301296 ), from Peking University (grants BMU2018MX020 , PKU2017LCX05 ), the National Key Technology R&D Program of the Ministry of Science and Technology of the People's Republic of China ( 2016YFC1305400 ); NIDDK grant R01DK097020 , and Siemens Healthcare grant to Tufts Medical Center.
Funding Information:
Silvia Titan, MD, PhD, Shiyuan Miao, MS, Hocine Tighiouart, MS, Nan Chen, MD, Hao Shi, MBBS, Luxia Zhang, MD, MPH, Zuo Li, MD, Marc Froissart, MD, PhD, Peter Rossing, MD, DMSc, Anders Grubb, MD, PhD, Li Fan, MD, PhD, Michael Mauer, MD, Omran Bakoush, MD, PhD, Christina Wyatt, MD, Michael G. Shlipak, MD, MPH, Tariq Shafi, MD, MBBS, Lesley A. Inker, MD, MS, and Andrew S. Levey, MD. Research idea and study design: ASL, LAI; data acquisition: NC, HS, LZ, ZL, MF, PR, AG, LF, MM, OB, CW, MGS TS, LAI, ASL; data analysis/interpretation: ST, SM, HT, LAI, ASL; statistical analysis: ST, SM, HT, LAI, ASL; supervision or mentorship: LAI, ASL. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate. CKD-EPI was supported by grants U01DK067651 and U01DK35073. AGES-Kidney was supported by a grant from NIH (R01 DK082447 and supplement 01A1S1 to ASL), contract from the NIA (N01-AG-1-2100 and HHSN27120120022C), the Icelandic Heart Association (Hjartavernd) and the Icelandic Parliament (Althingi), and the American Recovery Act (3R01DK082447-01A1S1). MESA-Kidney was supported by R01DK087961. HIV Study was funded by Gilead Sciences, Inc under an investigator-initiated protocol (NCRR L1RR025752) and supported by the NCRR and the National Center for Advancing Translational Sciences, NIH, through grants UL1 RR025752 (Tufts Medical Center) and UL1 RR029887 (Mount Sinai School of Medicine) and also the Center for Clinical and Translational Sciences through grant UL1 RR025777 (University of Alabama at Birmingham). Support was also received from international collaborative research grant no. 13430720800 from the Science and Technology Commission of Shanghai Municipality to Shanghai Jiao Tong University School of Medicine, Multi-Center Clinical Research Project (No: DLY201510); grant ID 201502010, National Health and Health Council (previously Ministry of Health), from 2015 through 2018; National Natural Science Foundation of China (grants 81771938, 91846101, 81301296), from Peking University (grants BMU2018MX020, PKU2017LCX05), the National Key Technology R&D Program of the Ministry of Science and Technology of the People's Republic of China (2016YFC1305400); NIDDK grant R01DK097020, and Siemens Healthcare grant to Tufts Medical Center. Dr Inker reports grants from the NIH and the National Kidney Foundation, other from Retrophin, other from Omeros, other from Dialysis Clinic Inc, and other from Reata, outside the submitted work. Dr Levey reports grants from NIH, outside the submitted work. Drs Inker and Levey have a patent ?Precise estimation of glomerular filtration rate from multiple biomarkers? patent number PCT/US2015/044567 pending. Dr Zhang reports grants from AstraZeneca, outside the submitted work. Dr Shafi reports personal fees from Siemens, University of California Irvine, University of Mississippi Medical Center, Hershey Medical Center, and University of Tennessee, outside the submitted work. Dr Shlipak is a Scientific Advisor for TAI Diagnostics. Dr Rossing reports grants, personal fees, and other from Novo Nordisk; grants and personal fees from Astra Zeneca; and personal fees from Astellas, Boehringer Ingelheim, Bayer, Eli Lilly, and Gilead, outside the submitted work. The other authors declare that they have no relevant financial interests. The authors appreciate the collaboration of Vilmundur Gudnason (University of Iceland, Reykjavik, Iceland & Icelandic Heart Association, Kopavogur, Iceland). The authors acknowledge the valuable contributions of the other investigators, staff, and participants of the MESA Study (supported by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from NHLBI, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from NCATS). A full list of participating investigators and institutions can be found at www.mesa-nhlbi.org. Received January 31, 2020. Evaluated by 3 external peer reviewers and a statistician, with direct editorial input from an Associate Editor, who served as Acting Editor-in-Chief. Accepted in revised form April 7, 2020. The involvement of an Acting Editor-in-Chief was to comply with AJKD's procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.
Funding Information:
Dr Inker reports grants from the NIH and the National Kidney Foundation, other from Retrophin, other from Omeros, other from Dialysis Clinic Inc, and other from Reata, outside the submitted work. Dr Levey reports grants from NIH, outside the submitted work. Drs Inker and Levey have a patent “Precise estimation of glomerular filtration rate from multiple biomarkers” patent number PCT/US2015/044567 pending. Dr Zhang reports grants from AstraZeneca, outside the submitted work. Dr Shafi reports personal fees from Siemens, University of California Irvine, University of Mississippi Medical Center, Hershey Medical Center, and University of Tennessee, outside the submitted work. Dr Shlipak is a Scientific Advisor for TAI Diagnostics. Dr Rossing reports grants, personal fees, and other from Novo Nordisk; grants and personal fees from Astra Zeneca; and personal fees from Astellas, Boehringer Ingelheim, Bayer, Eli Lilly, and Gilead, outside the submitted work. The other authors declare that they have no relevant financial interests.